



**HAL**  
open science

## Metabolic reprogramming of LPS-stimulated human lung macrophages involves tryptophan metabolism and the aspartate-arginosuccinate shunt

Fanta Fall, Elodie Lamy, Marion Brollo, Emmanuel Naline, Natacha Lenuzza, Etienne Thévenot, Philippe Devillier, Stanislas Grassin-Delyle

### ► To cite this version:

Fanta Fall, Elodie Lamy, Marion Brollo, Emmanuel Naline, Natacha Lenuzza, et al.. Metabolic reprogramming of LPS-stimulated human lung macrophages involves tryptophan metabolism and the aspartate-arginosuccinate shunt. PLoS ONE, 2020, 15 (4), pp.e0230813. 10.1371/journal.pone.0230813 . inserm-02543848

**HAL Id: inserm-02543848**

**<https://inserm.hal.science/inserm-02543848v1>**

Submitted on 15 Apr 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## RESEARCH ARTICLE

# Metabolic reprogramming of LPS-stimulated human lung macrophages involves tryptophan metabolism and the aspartate-arginosuccinate shunt

Fanta Fall<sup>1</sup>, Elodie Lamy<sup>1</sup>, Marion Brollo<sup>2</sup>, Emmanuel Naline<sup>2,3</sup>, Natacha Lenuzza<sup>4</sup>, Etienne Thévenot<sup>4</sup>, Philippe Devillier<sup>2,3</sup>, Stanislas Grassin-Delyle<sup>1,3\*</sup>

**1** Infection et inflammation, Université Paris-Saclay, UVSQ, INSERM, Montigny le Bretonneux, France, **2** Laboratoire Mécanismes moléculaires et pharmacologiques de l'obstruction bronchique, Université Paris-Saclay, UVSQ, Suresnes, France, **3** Hôpital Foch, Département des maladies des voies respiratoires, Suresnes, France, **4** Laboratory for Data Sciences and Decision, CEA, LIST, MetaboHUB, Gif-sur-Yvette, France

\* [stanislas.grassin-delyle@uvsq.fr](mailto:stanislas.grassin-delyle@uvsq.fr)



## OPEN ACCESS

**Citation:** Fall F, Lamy E, Brollo M, Naline E, Lenuzza N, Thévenot E, et al. (2020) Metabolic reprogramming of LPS-stimulated human lung macrophages involves tryptophan metabolism and the aspartate-arginosuccinate shunt. *PLoS ONE* 15 (4): e0230813. <https://doi.org/10.1371/journal.pone.0230813>

**Editor:** Michal A. Olszewski, University of Michigan Health System, UNITED STATES

**Received:** September 27, 2019

**Accepted:** March 9, 2020

**Published:** April 8, 2020

**Copyright:** © 2020 Fall et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was supported by the French Ministry of Higher Education and Research (PhD grant, Fanta Fall) and by the Chancellerie des Universités de Paris (Legs Gaston Poix).

**Competing interests:** The authors have declared that no competing interests exist.

## Abstract

Lung macrophages (LM) are in the first line of defense against inhaled pathogens and can undergo phenotypic polarization to the proinflammatory M1 after stimulation with Toll-like receptor agonists. The objective of the present work was to characterize the metabolic alterations occurring during the experimental M1 LM polarization. Human LM were obtained from resected lungs and cultured for 24 hrs in medium alone or with 10 ng.mL<sup>-1</sup> lipopolysaccharide. Cells and culture supernatants were subjected to extraction for metabolomic analysis with high-resolution LC-MS (HILIC and reverse phase -RP- chromatography in both negative and positive ionization modes) and GC-MS. The data were analyzed with R and the Worklow4Metabolomics and MetaboAnalyst online infrastructures. A total of 8,741 and 4,356 features were detected in the intracellular and extracellular content, respectively, after the filtering steps. Pathway analysis showed involvement of arachidonic acid metabolism, tryptophan metabolism and Krebs cycle in the response of LM to LPS, which was confirmed by the specific quantitation of selected compounds. This refined analysis highlighted a regulation of the kynurenin pathway as well as the serotonin biosynthesis pathway, and an involvement of aspartate-arginosuccinate shunt in the malate production. Macrophages M1 polarization is accompanied by changes in the cell metabolome, with the differential expression of metabolites involved in the promotion and regulation of inflammation and antimicrobial activity. The analysis of this macrophage immunometabolome may be of interest for the understanding of the pathophysiology of lung inflammatory diseases.

## Introduction

Lung macrophages are in the first line of defense against inhaled pathogens. They are major effectors of the immune response as they express membrane receptors, including Toll-like receptors (TLRs), able to recognize conserved microbial ligands [1]. Once activated, TLRs induce the production of a pattern of cytokines, chemokines and mediators, such as metabolites from the arachidonic acid pathway, involved in the inflammatory response and characteristics of a macrophage engagement towards a M1 polarization state [1, 2]. Lipopolysaccharide (LPS) is the archetypal TLR ligand for the induction of M1 macrophage polarization [1]. Like allergens (e.g. ragweed pollen, house dust extract, and cat dander) or air pollutants, LPS binds to and activates TLR4, the first subtype among the TLR family to be identified in humans. Beyond this role in cell signaling, TLRs also play a role in the primary function of macrophages, consisting in the phagocytosis and killing of pathogens [3]. For phagocytosis, the production of hydrolytic enzymes and reactive oxygen species (ROS) is required, the latter also resulting from oxidase or lipoxygenase enzyme metabolism [4]. The enzymatic machinery is therefore modulated following the presence of microorganisms, and more generally by the external environment, and consequently the resulting production of metabolites varies, being likely to adapt to the different stimuli to which macrophages can be exposed [5]. Cell metabolism and macrophages functions are tightly linked, as already shown in murine bone-marrow-derived macrophages. Hence, the presence of PGE<sub>2</sub>, one on the main arachidonic acid derivative, is necessary to the LPS-induced production of the precursor of the pro-inflammatory cytokine IL-1 $\beta$  [6]; LPS also induces an increased glycolysis and succinate production, necessary to the increase of IL-1 $\beta$  expression and also driving the production of ROS [7, 8]; finally, the TLR4 agonist MPLA induces mouse resistance to systemic infection with *Staphylococcus aureus* and *Candida albicans* by reprogramming macrophage metabolism, with increased glycolysis and oxidative phosphorylation and rewiring of malate/NADH shuttling [9]. Therefore, the understanding of macrophage metabolic reprogramming has become a key focus in fields such as infection [10], inflammation [11], cancer [12] and immune disorders [13]. With respect to lung pathogenesis, macrophages also play a role in infections and inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD), where they can undergo a phenotypic differentiation [14–17]. In these cases, TLRs are of prime importance for their role in the recognition of pathogens during infections and in microbe-induced acute exacerbations of asthma and COPD [18, 19]. However, the only reports of macrophage metabolic reprogramming in lung diseases until now were in a mouse model of fibrosis [20], in alveolar macrophages from LPS treated mice [21] and in smoker's or/and *Mycobacterium tuberculosis*-infected alveolar macrophages [22]. Since metabolic changes associated with the stimulation of TLRs in human lung macrophages were not yet described, the objective of the present study was to perform an extensive intra- and extracellular metabolomic characterization of LPS-induced alterations in human lung macrophages using a combined untargeted liquid chromatography high-resolution mass spectrometry and gas chromatography mass spectrometry approach [23].

## Materials and methods

### Patient population

The use of resected lung tissue was approved by the regional investigational review board (Comité de Protection des Personnes Ile de France VIII, Boulogne-Billancourt, France) and the patients undergoing surgical lung resection gave their written informed consent. Lung tissue was obtained from 10 patients with the following demographic characteristics: (median

[25<sup>th</sup>-75<sup>th</sup> percentiles]) age: 67.5 years [56.75–75.5]; 7 males, 3 females; body mass index: 24 kg/m<sup>2</sup> [18.75–26.25]; current tobacco smokers/ex-tobacco smokers/pipe smoker: 4/6/1; pack-years: 30 [15–80]; and % FEV1 predicted: 109% [81–121]. One patient was suffering from COPD (as defined by a post-bronchodilator FEV1/FVC ratio <0.7; GOLD 2 stage) and none had undergone chemotherapy or radiotherapy prior to surgical lung resection.

## Reagents

Penicillin, streptomycin, L-glutamine, LPS from *Escherichia coli* (serotype K12), fatty acid methyl esters (FAMES), LC-MS-grade ammonium formate and formic acid (98%) were purchased from Sigma Aldrich (Saint Quentin Fallavier, France). RPMI 1640 medium, phosphate-buffered saline, and fetal calf serum (FCS) were obtained from Eurobio Biotechnology (Les Ulis, France). LC-MS-grade methanol, acetonitrile, chloroform, isopropanol and water were from Fisher Scientific (Illkirch, France). All cell culture plastics were purchased from CML (Nemours, France).

## Cell culture

Human lung macrophages were isolated and cultured as previously described [1]. 2 million cells were cultured for 24 hrs in medium alone or with 10 ng.mL<sup>-1</sup> LPS. Supernatants were collected and centrifuged at 2000 rpm for 5 min at 4°C, then frozen at -80°C. Adherent macrophages were washed twice with sterile cold PBS. For LC-MS analysis, the macrophages were collected with 500 µL of methanol/water (1:1); for GC-MS analysis 1 mL of acetonitrile/isopropanol/water (3:3:2) was used. The plates were left at -80°C for 20 min then scraped with a pipette tip to recover the cells and samples were kept at -80°C until analysis.

## Metabolomic analysis

**Liquid chromatography-high resolution mass spectrometry.** Sample preparation was adapted from the method described by Bligh and Dyer [24]. For supernatants, 500 µL of methanol/water (1:1) were added to 100 µL of culture medium. Then, for both supernatants and cells, 500 µL of chloroform were added. The mixture was sonicated for 10 min, stir for 10 min and centrifuged at 10000 rpm for 5 mins to achieve a biphasic separation with the upper phase containing polar compounds and the lower fraction nonpolar compounds. 2x200 µL of each phase were collected in Eppendorf tubes and dried under vacuum. One of each 4 dried extracts was reconstituted with 75 µL of each of the following mixtures: formate/acetonitrile (20:80 v/v) and carbonate/acetonitrile (20:80 v/v) for extracts from the upper phase subsequently analysed with hydrophilic interaction liquid chromatography (HILIC); formate/acetonitrile (80:20 v/v) and carbonate/acetonitrile (80:20 v/v) for extracts from the lower phase subsequently analysed with reverse phase (RP) chromatography. Quality control samples were prepared by pooling 5 µL of each extracted sample.

LC-HRMS analysis was adapted from a previously described method [23] and each sample was injected four times, with HILIC and RP chromatography, both in the negative and positive ionization modes. Chromatography was performed with an UltiMate 3000 Quaternary Rapid Separation Pump (Thermo Scientific Dionex, Les Ulis, France) and the separation was performed under gradient elution using 4 different mobile phase systems consisting of mixtures of acetonitrile with either solvent A (10 mM pH 3.8 ammonium formate) for the positive ionization mode or solvent B (20 mM pH 9.2 ammonium carbonate) for the negative ionization mode.

A SeQuant 4.6 mm x 150 mm, 5 µm i.d. ZIC-pHILIC column (AIT France, Houilles, France) was used for HILIC chromatography. For the positive ionization mode, gradient

started with 5% solvent A until 3 min, then increased to reach 95% at 25 min and maintained for 5 more mins, then back to 5% and equilibrated for 10 mins. For the negative ionization mode, gradient started with 8% solvent B until 3 min, then increased to reach 92% at 25 min and maintained for 5 more mins, then back to 8% and equilibrated for 10 mins. Flow rate was 0.3 mL/min, curve gradient parameter set at 5, oven temperature 40°C and total run time 40 mins.

A Hypersil Gold C18 column 2.1 mm x 100 mm, 1.9 µm i.d. (Thermo Scientific Dionex) was used for RP chromatography. For the positive ionization mode, gradient started with 90% solvent A until 3 min, then decreased to reach 5% at 25 min and maintained for 8 more mins, then returning to 90% A for 5 mins. For the negative ionization mode, gradient started with 90% solvent B until 3 min, then decreased to reach 5% at 25 min and maintained for 8 more mins, then returning to 90% B for 5 mins. Flow rate was 0.3 mL/min, oven temperature 40°C and total run time 40 mins.

Mass spectrometry was performed with an hybrid quadrupole-orbitrap Q-Exactive mass spectrometer (ThermoFisher) equipped with an heated electrospray ionization (ESI) source operating in positive (ESI+) or negative (ESI-) ionization modes. The ESI and acquisition parameters for the different modes are shown in [S1 Table](#). Auxiliary gas heater temperature was set at 100°C, resolution at 70,000 and AGC target at 10<sup>6</sup>. The acquisition scan-range was split into 3 segments as previously described [23]: *m/z* 60–300; 300–600; 600–900. Xcalibur software (ThermoFisher) was used for system controlling and data acquisition.

**Gas chromatography-mass spectrometry.** Samples were prepared according to the method described by Fiehn [25]. For supernatants, 1 mL of acetonitrile/isopropanol/water (3:3:2) was added to 30 µL of medium. The supernatant and cell samples were then vortexed for 10 s, shaken for 5 mins, centrifuged at 14 000 rpm for 2 mins. 450 µL were recovered and dried under vacuum. The residue was reconstituted with 450 µL of acetonitrile/water 50:50 (1:1) degassed with nitrogen and centrifuged for 2 mins at 14 000 rpm. The residue was reconstituted with 10 µL of methoxyamine (MEOX) (20 mg/mL in pyridine), vortexed for 30 s, and kept at 30°C for 90 mins. Finally, 75 µL of N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) spiked with a mixture of FAME internal standards (10 µL of FAMEs for 1 mL of MSTFA) were added and the extract kept at 37°C for 30 mins. After derivation the samples were immediately transferred into injection vials.

Gas chromatography was performed on a Trace 1300 system (ThermoFisher) with an Upti-bond 5 Premium column 30 m x 0.25 mm x 0.25 mm (Interchim, Montluçon, France) and helium as a carrier gas at a flow rate of 1 mL/min. The injection volume was 1 µL. The temperature ramp was as follows: 60°C for 1 min, then an increase up to 325°C at 10°C/min. This temperature was maintained for 10 mins and total acquisition time was 37.5 mins. The detection was performed with a TSQ8000 mass spectrometer (ThermoFisher). The electron impact (EI) ion source was held at 230°C and an energy of 70 eV was used. Acquisition was performed in the full scan mode (*m/z* 50–600) with an acquisition rate of 20 spectrum/s. Xcalibur software (ThermoFisher) was used for system controlling and data acquisition.

**Data processing.** LC-MS raw files were first converted to mzML and centroidized with msConvert [26], then processed using IPO [27] and XCMS (v1.50.1) [28] packages running under R. The CentWave algorithm [29] was used for automatic peak picking, with parameters optimized with IPO. For GC-MS, the raw files were converted to CDF format. The data were analyzed with Workflow4Metabolomics using the metaMS, XCMS and CAMERA packages [28, 30, 31] that extract the peaks, align them, correct the analytical drift and perform annotation of adducts and isotopes.

Features detected in biological samples with a mean intensity less than 3-fold the intensity observed in blank samples, or features detected in blank samples only were filtered out to limit

**Table 1. Features detected in the intracellular metabolome analysis.**

| Analysis | Chromatography | Polarity | Initial number of features | After Filtering |
|----------|----------------|----------|----------------------------|-----------------|
| LC-MS    | HILIC          | +        | 16,588                     | 2,935           |
|          |                | -        | 11,613                     | 4,592           |
|          | RP             | +        | 9,772                      | 867             |
|          |                | -        | 4,407                      | 154             |
| GC-MS    | GC             | NA       | -                          | 193             |

<https://doi.org/10.1371/journal.pone.0230813.t001>

the number of false positive peaks. Features with a CV greater than 30% in the quality control samples were also filtered out. Batch correction, quality control checks and statistics were performed with Workflow4Metabolomics [32, 33]. Statistical analysis was also performed with Workflow4Metabolomics and MetaboAnalyst 4.0 using uni- or multivariate analysis and pathway analysis based on Mummichog [34]. Levels of metabolite annotation were defined as follows: level 0, which is the strongest level of annotation and includes stereochemistry discrimination; level 1 that requires the use of a chemical standard and at least two orthogonal techniques (e.g., accurate mass and retention time); level 2 is confirmation by a class-specific standard; level 3 by one parameter (e.g., accurate mass); level 4 is the feature-level without annotation [35]. HMDB, The Golm Metabolome Database and NIST [36, 37] were used for database queries.

## Results

### Untargeted metabolomic analysis

For the intracellular metabolome, the combination of the different LC-MS and GC-MS methods allowed the detection of 42,573 features in control and LPS-treated samples (Table 1). HILIC was the most contributive, followed with RP chromatography and GC-MS and a total of 8,741 features were remaining after the filtering steps.

For the extracellular metabolome, 45,258 features were first detected, with 4,356 remaining after filtering (Table 2). RP chromatography allowed the detection of the highest number of features, followed with HILIC and GC-MS.


### Multivariate analysis

Models were built with Partial Least-Squares—Discriminant Analysis (PLS-DA) for each condition and are shown in Fig 1A and 1B for the intracellular and extracellular metabolomes, respectively. The models for the intracellular metabolome allowed the distinction between control and treated cells with taking into account 2 components for the four analytical conditions. Each of these 2 components explained between 7.1 and 26.1% of the variability. On the other hand, with respect to the extracellular metabolome, 2 components were enough to discriminate control and treated cells for HILIC in the positive ionization mode, but 3

**Table 2. Features detected in the extracellular metabolome analysis.**

| Analysis | Chromatography | Polarity | Initial number of features | After Filtering |
|----------|----------------|----------|----------------------------|-----------------|
| LC-MS    | HILIC          | +        | 11,411                     | 840             |
|          |                | -        | 17,821                     | 1,055           |
|          | RP             | +        | 14,426                     | 2,160           |
|          |                | -        | 1,326                      | 27              |
| GC-MS    | GC             | NA       | -                          | 274             |

<https://doi.org/10.1371/journal.pone.0230813.t002>




**Fig 1. Partial Least Squares—Discriminant Analysis (PLS-DA).** PLS-DA was performed for the intracellular (A) and extracellular (B) HILIC, RP and GC-MS analysis of the human macrophage metabolome ( $n = 10$ ) in cells cultured for 24 hrs with (green) or without (red) LPS ( $10 \text{ ng mL}^{-1}$ ). HILIC: hydrophilic interaction liquid chromatography; RP: reverse phase; GC: gas chromatography.

<https://doi.org/10.1371/journal.pone.0230813.g001>

components were suggested by cross-validation to discriminate samples categories in the other analytical conditions. Although all models well fitted the data ( $R^2Y > 0.9$ ), their prediction capacity was poor with  $Q^2Y < 0.3$ , except for the analysis of the extracellular content with HILIC in the positive ionization mode ( $Q^2Y = 0.5$ ). The features contributing the most to each model (assessed with Variable Importance in Projection (VIP) score) were then used for hierarchical clustering and for pathway analysis. Hierarchical clustering for the intracellular and extracellular metabolomes is depicted in Fig 2A and 2B, showing that an excellent categorization was achieved between control and LPS-treated macrophages for the majority of the different analytical conditions. Two categories of features, i.e. up- or down-regulated in control or LPS groups, are clearly distinguishable for the analysis of the intracellular content with HILIC in the positive and negative ionization mode.

### Pathway analysis

Pathway analysis for the LC-MS analysis of the intracellular content revealed differential expression of arachidonic acid metabolites in LPS-treated macrophages (Fig 3). Furthermore, GC-MS analysis suggested modulations in metabolites from tryptophan metabolism and Krebs cycle. Metabolites identified by the statistical analysis to be the most contributing to the



**Fig 2. Hierarchical clustering analysis.** The top 50 differentially expressed metabolites for the intracellular (A) and extracellular (B) HILIC, RP and GC-MS analysis of the human macrophage metabolome ( $n = 10$ ) in cells cultured for 24 hrs with (green) or without (red) LPS ( $10 \text{ ng.mL}^{-1}$ ) were used for hierarchical clustering. Metabolites in red are upregulated, those in blue downregulated.

<https://doi.org/10.1371/journal.pone.0230813.g002>

different models are shown in Table 3, with most features corresponding to arachidonic acid metabolites. Since the production of arachidonic acid derivatives after stimulation of lung macrophages with LPS is already well documented [38–42], we then focused on the exploration of tryptophan metabolism and Krebs cycle pathway.

### Targeted metabolic profiling

Specific targeted LC-MS methods were developed for the quantitative analysis of selected compounds from tryptophan metabolism and Krebs cycle and the results are depicted in Fig 4. For tryptophan metabolism, a LPS-induced decrease in the tryptophan concentration and an increase in concentrations of compounds from the kynurenine pathway (kynurenine and quinolinic acid) were observed in both the intracellular and extracellular compartments (quinolinic acid increase was statistically significant in the extracellular content only). Accordingly, the concentration of hydroxytryptophan, a metabolite of the other tryptophan degradation pathway leading to serotonin synthesis, was also increased in the intracellular content. For Krebs cycle metabolites, an increase in the concentration of malate was observed (statistically significant for the intracellular content only), whereas succinate and fumarate were found unaltered. In a similar model with murine bone-marrow derived macrophages [43], the increased malate production was explained by the induction of the arginosuccinate shunt, involving arginosuccinate, fumarate and malate. In line with this, intracellular arginosuccinate was measured in human lung macrophages and a 336% increase in the production was observed (S1 Fig).






Table 3. Features differentially expressed between control and LPS samples in cell and supernatant samples.

| Feature              | <i>m/z</i> | RT    | Ionization Mode | Method | Log <sub>2</sub> (Fold Change) | Proposed molecular formula                                    | Proposed annotation               | Level ID | Δppm |
|----------------------|------------|-------|-----------------|--------|--------------------------------|---|-----------------------------------|----------|------|
| <b>Intracellular</b> |            |       |                 |        |                                |   |                                   |          |      |
| 1                    | 221.0919   | 18.5  | Pos             | HILIC  | 2.3                            | C <sub>11</sub> H <sub>12</sub> N <sub>2</sub> O <sub>3</sub> | Hydroxy-tryptophan                | 3        | 1    |
| 2                    | 299.2003   | 7.3   | Pos             | HILIC  | 4.0                            | C <sub>20</sub> H <sub>26</sub> O <sub>2</sub>                | 3,4-didehydro-retinoate           | 3        | 1    |
| 3                    | 301.2163   | 7.6   | Pos             | HILIC  | 5.4                            | C <sub>20</sub> H <sub>28</sub> O <sub>2</sub>                | 4-hydroxyretinal                  | 3        | 0    |
| 4                    | 305.0864   | 14.8  | Pos             | HILIC  | 1.2                            | C <sub>12</sub> H <sub>17</sub> O <sub>9</sub>                | -                                 | 3        | 1    |
| 5                    | 317.2112   | 7.9   | Pos             | HILIC  | 4.4                            | C <sub>20</sub> H <sub>28</sub> O <sub>3</sub>                | 15-deoxy-PGJ2                     | 3        | 0    |
| 6                    | 319.2270   | 7.7   | Pos             | HILIC  | 5.3                            | C <sub>20</sub> H <sub>30</sub> O <sub>3</sub>                | Leukotriene A4                    | 3        | 1    |
| 7                    | 344.2438   | 18.4  | Pos             | HILIC  | 3.7                            | C <sub>18</sub> H <sub>34</sub> NO <sub>5</sub>               |                                   | 4        | 2    |
| 8                    | 393.2260   | 7.4   | Pos             | HILIC  | 5.7                            | C <sub>22</sub> H <sub>32</sub> O <sub>6</sub>                | 10-hydroperoxy-H4-neuroprostane   | 3        | 3    |
| 9                    | 120.0449   | 4.9   | Neg             | HILIC  | 4.0                            | C <sub>7</sub> H <sub>7</sub> NO                              | -                                 | 3        | 4    |
| 10                   | 164.0346   | 4.9   | Neg             | HILIC  | 3.8                            | C <sub>8</sub> H <sub>7</sub> NO <sub>3</sub>                 | Pyridoxolactone                   | 3        | 4    |
| 11                   | 167.0171   | 17.7  | Neg             | HILIC  | 2.2                            | C <sub>2</sub> H <sub>5</sub> N <sub>3</sub> O <sub>6</sub>   | -                                 | 4        | 7    |
| 12                   | 194.0451   | 3.8   | Neg             | HILIC  | 6.7                            | C <sub>9</sub> H <sub>9</sub> NO <sub>4</sub>                 | Hydroxyhippuric acid              | 3        | 4    |
| 13                   | 315.1952   | 7.2   | Neg             | HILIC  | 4.9                            | C <sub>20</sub> H <sub>28</sub> O <sub>3</sub>                | 15-deoxy-PGJ2                     | 3        | 4    |
| 14                   | 333.2061   | 7.1   | Neg             | HILIC  | 8.7                            | C <sub>20</sub> H <sub>30</sub> O <sub>4</sub>                | Prostaglandin A2                  | 3        | 3    |
| 15                   | 334.2095   | 5.2   | Neg             | HILIC  | 5.0                            | C <sub>15</sub> H <sub>30</sub> N <sub>2</sub> O <sub>6</sub> | -                                 | 4        | 4    |
| 16                   | 351.2160   | 7.1   | Neg             | HILIC  | 4.8                            | C <sub>20</sub> H <sub>32</sub> O <sub>5</sub>                | Thromboxane A2                    | 3        | 5    |
| 17                   | 353.2325   | 9.7   | Neg             | HILIC  | 2.7                            | C <sub>20</sub> H <sub>34</sub> O <sub>5</sub>                | Prostaglandin E1                  | 3        | 2    |
| 18                   | 368.2432   | 10.4  | Neg             | HILIC  | 5.1                            | C <sub>18</sub> H <sub>30</sub> NO <sub>5</sub>               | -                                 | 4        | 1    |
| 19                   | 381.2632   | 8.9   | Neg             | HILIC  | 10.3                           | C <sub>22</sub> H <sub>32</sub> N <sub>4</sub> O <sub>4</sub> | -                                 | 3        | 4    |
| 20                   | 383.2425   | 5.1   | Neg             | HILIC  | 5.5                            | C <sub>21</sub> H <sub>35</sub> O <sub>6</sub>                |                                   | 4        | 3    |
| 21                   | 385.2217   | 14.9  | Neg             | HILIC  | 2.8                            | C <sub>20</sub> H <sub>34</sub> O <sub>7</sub>                | Dihydro-trihydroxy-leukotriene B4 | 3        | 4    |
| 22                   | 436.1933   | 7.0   | Neg             | HILIC  | 5.4                            | C <sub>18</sub> H <sub>26</sub> N <sub>7</sub> O <sub>6</sub> | -                                 | 4        | 3    |
| 23                   | 387.1448   | 18.7  | Pos             | RP     | 9.5                            | C <sub>21</sub> H <sub>22</sub> O <sub>7</sub>                | -                                 | 3        | 3    |
| 24                   | 134.1      | 12.40 | -               | GC     | 8.4                            | C <sub>4</sub> H <sub>6</sub> O <sub>5</sub>                  | Malic acid                        | 1        |      |
| 25                   | 167.0      | 15.19 | -               | GC     | 1.3                            | C <sub>7</sub> H <sub>5</sub> NO <sub>4</sub>                 | Quinolinic acid                   | 1        |      |
| <b>Extracellular</b> |            |       |                 |        |                                |   |                                   |          |      |
| 1                    | 136.0398   | 14.56 | Pos             | HILIC  | 8.3                            | C <sub>7</sub> H <sub>5</sub> NO <sub>2</sub>                 | -                                 | 3        |      |
| 2                    | 405.2630   | 7.25  | Pos             | HILIC  | 3.4                            | C <sub>24</sub> H <sub>36</sub> O <sub>5</sub>                | -                                 | 3        |      |
| 3                    | 757.4305   | 7.60  | Pos             | HILIC  | 6.3                            | C <sub>39</sub> H <sub>64</sub> O <sub>14</sub>               | -                                 | 3        |      |
| 4                    | 334.2115   | 6.0   | Neg             | HILIC  | 3.9                            | C <sub>15</sub> H <sub>30</sub> N <sub>2</sub> O <sub>6</sub> |                                   | 5        | 2    |
| 5                    | 351.2190   | 6.79  | Neg             | HILIC  | 3.6                            | C <sub>20</sub> H <sub>32</sub> O <sub>5</sub>                | Prostaglandin E2                  | 3        |      |

<https://doi.org/10.1371/journal.pone.0230813.t003>

[51], highlighting the interest of confirming with primary cells the results obtained with available surrogates.

In addition to molecules from arachidonic acid metabolism, pathway analysis revealed a role for the tryptophan metabolism and Krebs cycle during macrophage M1 polarisation. The role of eicosanoids in the macrophage inflammatory regulation and its resolution is already well established, with increased LPS-induced prostaglandin and leukotriene production [38–40, 52], the inhibitory role of PGE<sub>2</sub> and regulating role of 15-lipoxygenases in cytokine production [2, 53–55]. Hydroxy-tryptophan, kynurenine and quinolinic acid are downstream metabolites of tryptophan metabolism and were quantified in the present study. Hydroxy-tryptophan is the precursor of serotonin, whereas kynurenine and quinolinic acid belong to the kynurenine pathway. Hence, the depletion of tryptophan is the consequence of both the LPS-induced increase in indoleamine-2,3-dioxygenase (IDO), leading to the formation of kynurenine metabolites, as described in human pulmonary macrophages [56] and to the



**Fig 4. Targeted analysis.** Quantification of selected intracellular (A) and extracellular (B) metabolites from tryptophan metabolism and Krebs cycle in human lung macrophages cultured for 24 hrs with or without (control) LPS ( $10 \text{ ng} \cdot \text{mL}^{-1}$ ). Data are expressed in pg per  $10^6$  cells. ND: not detected.

<https://doi.org/10.1371/journal.pone.0230813.g004>

increase in tryptophan hydroxylase (TPH) activity, also occurring in macrophages in inflammatory conditions [57]. The effectors of the kynurenine pathway, expressed in epithelial cells and alveolar macrophages, were previously shown to be critical regulators of acute pulmonary inflammation in a murine model of lung transplantation [58]. In infectious disease models, IDO expression is increased by respiratory syncytial virus in human monocyte-derived dendritic cells and by IFN- $\gamma$  and HIV in human monocyte-derived macrophages [59, 60] and quinolinate is increased by HIV in monocyte-derived macrophages [49]. In the clinics, increased IDO and TPH activities were strongly associated to 30-day death and/or intensive care unit admission and/or 18 month mortality in patients with COPD exacerbations [61]; an increase in serum kynurenine and a decrease in tryptophan was observed in patients with pneumonia with correlations between IDO activity / kynurenine levels and severity or mortality [62], while kynurenine levels were associated with 28-day mortality in critically ill adult patients [63]. Evidence showing the involvement of tryptophan in the regulation of macrophage polarization is also available. For instance, the role of the kynurenine pathway in inducing changes in macrophage phenotypes was previously investigated in the murine macrophage cell line RAW 264.7 and the murine fibrosarcoma cell line MC57, showing a role for IDO in cell adhesion, metalloproteinase expression and in the expression and activity of the cyclooxygenase enzymes [64]. Culture of RAW264.7 macrophages in a tryptophan-deficient medium induced a 54% reduction in cell proliferation as compared with cells cultured in RPMI, which was restored by tryptophan supplementation. In these cells, tryptophan deficiency was also responsible of an increase in cell death and apoptosis, which was also reversible by tryptophan supplementation [65]. With respect to the production of signaling molecules, macrophages from indoleamine 2,3-dioxygenase 2 knockout mice produced higher amounts of IL-1 $\alpha$ , IL-6, IL-10, MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES after LPS stimulation than macrophages from wild-type mice. In line with this, the preincubation of IFN- $\gamma$ -primed induced pluripotent stem cell-derived human macrophages with INCB024360, an IDO1 inhibitor significantly impaired bacterial killing, which is a key feature of M1-polarized macrophages [66]. RAW264.7 macrophage cells and primary murine alveolar macrophages also showed increased IL-6, TNF- $\alpha$ ,

IFN- $\beta$ , and/or IL-1 $\beta$  production in the presence of 1-methyltryptophan another IDO pharmacological competitive inhibitor, following influenza infection [67]. On the other hand, overexpression of IDO enzyme in the murine macrophage cell line RAW264.7 suppressed IL-6, G-CSF, MCP-1, and MIP-1 $\beta$  production [68] while treatment of these cells with the metabolites indole-3-acetate and tryptamine significantly attenuates the expression of TNF- $\alpha$ , IL-1 $\beta$ , and MCP-1 [69]. The production of molecules involved in microbes killing was also affected since LPS and IFN- $\gamma$  stimulated RAW264.7 cells cultured in tryptophan-deficient medium demonstrated a significant reduction in iNOS expression in comparison to control cells, while cells cultured in the presence of tryptophan expressed significantly higher amounts of iNOS, leading to marked released amounts of NO [65]. Our results also strongly support a major role for tryptophan metabolism in lung macrophages during inflammation, suggesting the interest of a pharmacological approach to modulate this pathway in inflammatory lung diseases.

Then, a large increase in the production of malate, one metabolite from the Krebs cycle, was observed in response to LPS, as previously reported in bone-marrow derived mouse macrophages [43, 48], whereas succinate and fumarate levels were unchanged. Other groups reported either very modest or larger increases in succinate after stimulation with LPS of murine bone-marrow derived macrophages, with key roles for succinate in the induction of IL-1 $\beta$  through HIF-1 $\alpha$  [7, 43]. In their M1 polarisation model of murine bone-marrow derived macrophages, Jha and colleagues reported that malate accumulation was related to the induction of the arginosuccinate shunt, a pathway connecting the Krebs cycle with the urea cycle, involving aspartate, arginosuccinate, malate and fumarate. In their model, inhibiting this pathway with aminooxyacetic acid induced a concentration-dependant inhibition of the production of nitric oxide and IL-6, important effectors of antimicrobial activity and inflammatory reaction [43]. In line with these findings, we observed a 336% increase in the production of arginosuccinate in LPS-stimulated human lung macrophages, also suggesting a potential link between metabolism and immune functions in primary human cells.

All the changes in metabolite concentrations measured during the targeted analysis were consistent between the intracellular and extracellular compartments, suggesting that intracellularly produced metabolites may play an autocrine/paracrine role by being released in the cell environment in response to an inflammatory stimuli.

The main limit of the study is related to the patient population and sample size, which was limited to assess the effect of covariates such as age, smoking status or COPD. These covariates are known to affect the response of lung macrophages to TLR agonists; however, these changes greatly vary from one study to another. For example, some studies report increases in the LPS-induced cytokine production of alveolar macrophages from smoking or COPD patients [70, 71] whereas opposite findings were also reported by other groups [72, 73] and in other cases, current smoking status had no effect on the production of cytokines in response to LPS [74, 75]. Altogether, these findings supports the concept whereby the LPS-induced production of cytokines by lung macrophages obtained from COPD, smokers, and healthy adults are similar, although this cannot be directly extrapolated to metabolomic analysis.

In conclusion, we described the use of an extensive combined GC- and LC-MS strategy for the metabolomic profiling of the LPS-induced M1 human lung macrophage polarization. The non-targeted analysis revealed the involvement of the arachidonic pathway, tryptophan metabolism and Krebs cycle during the M1 polarisation. Targeted analysis of selected compounds confirmed these findings and allowed the quantification of the identified metabolites and allowed to precise a role for the aspartate-arginosuccinate shunt. Knowing the role of macrophages in inflammatory lung diseases, a further detailed investigation of alterations occurring in these pathways in cells from patients with asthma or COPD should be of particular interest.

## Supporting information

**S1 Table. Mass spectrometry parameters for HILIC and reverse phase chromatography with positive or negative electrospray ionisation.**

(DOCX)

**S1 Fig. Quantification of intracellular arginosuccinate in human lung macrophages cultured for 24 hrs with or without (control) LPS (10 ng.mL<sup>-1</sup>).** Data are expressed in pg per 10<sup>6</sup> cells.

(TIF)

**S1 Data.**

(XLSX)

**S2 Data.**

(XLSX)

## Author Contributions

**Conceptualization:** Stanislas Grassin-Delyle.

**Data curation:** Natacha Lenuzza, Etienne Thévenot.

**Formal analysis:** Stanislas Grassin-Delyle.

**Funding acquisition:** Stanislas Grassin-Delyle.

**Investigation:** Fanta Fall, Elodie Lamy, Marion Brollo, Emmanuel Naline.

**Methodology:** Stanislas Grassin-Delyle.

**Project administration:** Emmanuel Naline, Stanislas Grassin-Delyle.

**Resources:** Stanislas Grassin-Delyle.

**Software:** Natacha Lenuzza, Etienne Thévenot.

**Supervision:** Etienne Thévenot, Philippe Devillier, Stanislas Grassin-Delyle.

**Validation:** Fanta Fall, Stanislas Grassin-Delyle.

**Writing – original draft:** Fanta Fall, Stanislas Grassin-Delyle.

**Writing – review & editing:** Elodie Lamy, Marion Brollo, Emmanuel Naline, Natacha Lenuzza, Etienne Thévenot, Philippe Devillier, Stanislas Grassin-Delyle.

## References

1. Grassin-Delyle S, Abrial C, Salvator H, Brollo M, Naline E, Devillier P. The Role of Toll-Like Receptors in the Production of Cytokines by Human Lung Macrophages. *Journal of innate immunity*. 2018;1–11. <https://doi.org/10.1159/000494463> PMID: 30557876.
2. Abrial C, Grassin-Delyle S, Salvator H, Brollo M, Naline E, Devillier P. 15-Lipoxygenases regulate the production of chemokines in human lung macrophages. *British journal of pharmacology*. 2015; 172(17):4319–30. <https://doi.org/10.1111/bph.13210> PMID: 26040494; PubMed Central PMCID: PMC4556470.
3. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. *Nature immunology*. 2015; 16(4):343–53. <https://doi.org/10.1038/ni.3123> PMID: 25789684; PubMed Central PMCID: PMC4507498.
4. Pinheiro CDS, Monteiro APT, Dutra FF, Bozza MT, Peters-Golden M, Benjamim CF, et al. Short-Term Regulation of FcγR-Mediated Phagocytosis by TLRs in Macrophages: Participation of 5-Lipoxygenase Products. *Mediators Inflamm*. 2017; 2017:2086840. <https://doi.org/10.1155/2017/2086840> PMID: 28894350; PubMed Central PMCID: PMC5574301.

5. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. *Cell metabolism*. 2012; 15(4):432–7. <https://doi.org/10.1016/j.cmet.2011.11.013> PMID: 22482726.
6. Zaslona Z, Palsson-McDermott EM, Menon D, Haneklaus M, Flis E, Prendeville H, et al. The Induction of Pro-IL-1beta by Lipopolysaccharide Requires Endogenous Prostaglandin E2 Production. *J Immunol*. 2017; 198(9):3558–64. <https://doi.org/10.4049/jimmunol.1602072> PMID: 28298525.
7. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. *Nature*. 2013; 496(7444):238–42. <https://doi.org/10.1038/nature11986> PMID: 23535595; PubMed Central PMCID: PMC4031686.
8. Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, et al. Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages. *Cell*. 2016; 167(2):457–70 e13. <https://doi.org/10.1016/j.cell.2016.08.064> PMID: 27667687; PubMed Central PMCID: PMC5863951.
9. Fensterheim BA, Young JD, Luan L, Kleinbard RR, Stothers CL, Patil NK, et al. The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism. *J Immunol*. 2018; 200(11):3777–89. <https://doi.org/10.4049/jimmunol.1800085> PMID: 29686054; PubMed Central PMCID: PMC5964009.
10. Gleeson LE, Sheedy FJ, Palsson-McDermott EM, Triglia D, O'Leary SM, O'Sullivan MP, et al. Cutting Edge: Mycobacterium tuberculosis Induces Aerobic Glycolysis in Human Alveolar Macrophages That Is Required for Control of Intracellular Bacillary Replication. *J Immunol*. 2016; 196(6):2444–9. <https://doi.org/10.4049/jimmunol.1501612> PMID: 26873991.
11. Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. *Nature*. 2018; 556(7699):113–7. <https://doi.org/10.1038/nature25986> PMID: 29590092; PubMed Central PMCID: PMC6047741.
12. Ryan DG, Murphy MP, Frezza C, Prag HA, Chouchani ET, O'Neill LA, et al. Coupling Krebs cycle metabolites to signalling in immunity and cancer. *Nat Metab*. 2019; 1:16–33. <https://doi.org/10.1038/s42255-018-0014-7> PMID: 31032474; PubMed Central PMCID: PMC6485344.
13. McGettrick AF, O'Neill LA. How metabolism generates signals during innate immunity and inflammation. *J Biol Chem*. 2013; 288(32):22893–8. <https://doi.org/10.1074/jbc.R113.486464> PMID: 23798679; PubMed Central PMCID: PMC3743468.
14. Byers DE, Holtzman MJ. Alternatively activated macrophages and airway disease. *Chest*. 2011; 140(3):768–74. Epub 2011/09/08. 140/3/768 [pii] <https://doi.org/10.1378/chest.10-2132> PMID: 21896520; PubMed Central PMCID: PMC3168852.
15. Dasgupta P, Keegan AD. Contribution of alternatively activated macrophages to allergic lung inflammation: a tale of mice and men. *J Innate Immun*. 2012; 4(5–6):478–88. Epub 2012/03/24. <https://doi.org/10.1159/000336025> [pii] PMID: 22440980.
16. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. *Nat Med*. 2008; 14(6):633–40. Epub 2008/05/20. <https://doi.org/10.1038/nm1770> [pii] PMID: 18488036; PubMed Central PMCID: PMC2575848.
17. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. *J Immunol*. 2008; 181(6):3733–9. Epub 2008/09/05. 181/6/3733 [pii] <https://doi.org/10.4049/jimmunol.181.6.3733> PMID: 18768823.
18. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. *American journal of respiratory and critical care medicine*. 2011; 184(6):662–71. <https://doi.org/10.1164/rccm.201104-0597OC> PMID: 21680942.
19. Busse WW, Lemanske RF Jr., Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. *Lancet*. 2010; 376(9743):826–34. [https://doi.org/10.1016/S0140-6736\(10\)61380-3](https://doi.org/10.1016/S0140-6736(10)61380-3) PMID: 20816549; PubMed Central PMCID: PMC2972660.
20. Xie N, Cui H, Ge J, Banerjee S, Guo S, Dubey S, et al. Metabolic characterization and RNA profiling reveal glycolytic dependence of profibrotic phenotype of alveolar macrophages in lung fibrosis. *American journal of physiology Lung cellular and molecular physiology*. 2017; 313(5):L834–L44. <https://doi.org/10.1152/ajplung.00235.2017> PMID: 28798256; PubMed Central PMCID: PMC5792180.
21. Mould KJ, Barthel L, Mohning MP, Thomas SM, McCubbrey AL, Danhorn T, et al. Cell Origin Dictates Programming of Resident versus Recruited Macrophages during Acute Lung Injury. *American journal of respiratory cell and molecular biology*. 2017; 57(3):294–306. <https://doi.org/10.1165/rcmb.2017-0061OC> PMID: 28421818; PubMed Central PMCID: PMC5625228.
22. Gleeson LE, O'Leary SM, Ryan D, McLaughlin AM, Sheedy FJ, Keane J. Cigarette Smoking Impairs the Bioenergetic Immune Response to Mycobacterium tuberculosis Infection. *American journal of*

- respiratory cell and molecular biology. 2018; 59(5):572–9. <https://doi.org/10.1165/rcmb.2018-0162OC> PMID: 29944387.
23. Fall F, Lenuzza N, Lamy E, Brollo M, Naline E, Devillier P, et al. A split-range acquisition method for the non-targeted metabolomic profiling of human plasma with hydrophilic interaction chromatography—high-resolution mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2019; 1128:121780. <https://doi.org/10.1016/j.jchromb.2019.121780> PMID: 31479891.
  24. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol*. 1959; 37(8):911–7. <https://doi.org/10.1139/o59-099> PMID: 13671378.
  25. Fiehn O. Metabolomics by Gas Chromatography-Mass Spectrometry: Combined Targeted and Untargeted Profiling. *Curr Protoc Mol Biol*. 2016; 114:30 4 1–4 2. <https://doi.org/10.1002/0471142727.mb3004s114> PMID: 27038389; PubMed Central PMCID: PMC4829120.
  26. Kessner D, Chambers M, Burke R, Agus D, Mallick P. ProteoWizard: open source software for rapid proteomics tools development. *Bioinformatics*. 2008; 24(21):2534–6. <https://doi.org/10.1093/bioinformatics/btn323> PMID: 18606607; PubMed Central PMCID: PMC2732273.
  27. Libiseller G, Dvorzak M, Kleb U, Gander E, Eisenberg T, Madeo F, et al. IPO: a tool for automated optimization of XCMS parameters. *BMC Bioinformatics*. 2015; 16:118. <https://doi.org/10.1186/s12859-015-0562-8> PMID: 25888443; PubMed Central PMCID: PMC4404568.
  28. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. *Analytical chemistry*. 2006; 78(3):779–87. <https://doi.org/10.1021/ac051437y> PMID: 16448051.
  29. Tautenhahn R, Bottcher C, Neumann S. Highly sensitive feature detection for high resolution LC/MS. *BMC Bioinformatics*. 2008; 9:504. <https://doi.org/10.1186/1471-2105-9-504> PMID: 19040729; PubMed Central PMCID: PMC2639432.
  30. Wehrens R, Weingart G, Mattivi F. metaMS: an open-source pipeline for GC-MS-based untargeted metabolomics. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2014; 966:109–16. <https://doi.org/10.1016/j.jchromb.2014.02.051> PMID: 24656939.
  31. Kuhl C, Tautenhahn R, Bottcher C, Larson TR, Neumann S. CAMERA: an integrated strategy for compound spectra extraction and annotation of liquid chromatography/mass spectrometry data sets. *Analytical chemistry*. 2012; 84(1):283–9. <https://doi.org/10.1021/ac202450g> PMID: 22111785; PubMed Central PMCID: PMC3658281.
  32. Guillon Y, Tremblay-Franco M, Le Corguille G, Martin JF, Petera M, Roger-Mele P, et al. Create, run, share, publish, and reference your LC-MS, FIA-MS, GC-MS, and NMR data analysis workflows with the Workflow4Metabolomics 3.0 Galaxy online infrastructure for metabolomics. *Int J Biochem Cell Biol*. 2017; 93:89–101. <https://doi.org/10.1016/j.biocel.2017.07.002> PMID: 28710041.
  33. Giacomoni F, Le Corguille G, Monsoor M, Landi M, Pericard P, Petera M, et al. Workflow4Metabolomics: a collaborative research infrastructure for computational metabolomics. *Bioinformatics*. 2015; 31(9):1493–5. <https://doi.org/10.1093/bioinformatics/btu813> PMID: 25527831; PubMed Central PMCID: PMC4410648.
  34. Li S, Park Y, Duraisingham S, Strobel FH, Khan N, Soltow QA, et al. Predicting network activity from high throughput metabolomics. *PLoS Comput Biol*. 2013; 9(7):e1003123. <https://doi.org/10.1371/journal.pcbi.1003123> PMID: 23861661; PubMed Central PMCID: PMC3701697.
  35. Chaleckis R, Meister I, Zhang P, Wheelock CE. Challenges, progress and promises of metabolite annotation for LC-MS-based metabolomics. *Curr Opin Biotechnol*. 2019; 55:44–50. <https://doi.org/10.1016/j.copbio.2018.07.010> PMID: 30138778.
  36. Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vazquez-Fresno R, et al. HMDB 4.0: the human metabolome database for 2018. *Nucleic Acids Res*. 2018; 46(D1):D608–D17. <https://doi.org/10.1093/nar/gkx1089> PMID: 29140435; PubMed Central PMCID: PMC5753273.
  37. Kopka J, Schauer N, Krueger S, Birkemeyer C, Usadel B, Bergmuller E, et al. GMD@CSB.DB: the Golm Metabolome Database. *Bioinformatics*. 2005; 21(8):1635–8. <https://doi.org/10.1093/bioinformatics/bti236> PMID: 15613389.
  38. Suzuki K, Yamamoto T, Sato A, Murayama T, Amitani R, Yamamoto K, et al. Lipopolysaccharide primes human alveolar macrophages for enhanced release of superoxide anion and leukotriene B4: self-limitations of the priming response with protein synthesis. *American journal of respiratory cell and molecular biology*. 1993; 8(5):500–8. <https://doi.org/10.1165/ajrcmb.8.5.500> PMID: 8386927.
  39. O'Sullivan MG, Chilton FH, Huggins EM Jr., McCall CE. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. *The Journal of biological chemistry*. 1992; 267(21):14547–50. PMID: 1634505.
  40. Rankin JA, Sylvester I, Smith S, Yoshimura T, Leonard EJ. Macrophages cultured in vitro release leukotriene B4 and neutrophil attractant/activation protein (interleukin 8) sequentially in response to

- stimulation with lipopolysaccharide and zymosan. *J Clin Invest*. 1990; 86(5):1556–64. <https://doi.org/10.1172/JCI114875> PMID: 2173722; PubMed Central PMCID: PMC296903.
41. Coffey MJ, Phare SM, Peters-Golden M. Prolonged exposure to lipopolysaccharide inhibits macrophage 5-lipoxygenase metabolism via induction of nitric oxide synthesis. *Journal of immunology*. 2000; 165(7):3592–8. <https://doi.org/10.4049/jimmunol.165.7.3592> PMID: 11034360.
  42. Hempel SL, Monick MM, Hunninghake GW. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. *The Journal of clinical investigation*. 1994; 93(1):391–6. <https://doi.org/10.1172/JCI116971> PMID: 8282809; PubMed Central PMCID: PMC293791.
  43. Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. *Immunity*. 2015; 42(3):419–30. <https://doi.org/10.1016/j.immuni.2015.02.005> PMID: 25786174.
  44. Adamson SX, Wang R, Wu W, Cooper B, Shannahan J. Metabolomic insights of macrophage responses to graphene nanoplatelets: Role of scavenger receptor CD36. *PloS one*. 2018; 13(11): e0207042. <https://doi.org/10.1371/journal.pone.0207042> PMID: 30403754; PubMed Central PMCID: PMC6221354.
  45. Zhao C, Tang Z, Yan J, Fang J, Wang H, Cai Z. Bisphenol S exposure modulate macrophage phenotype as defined by cytokines profiling, global metabolomics and lipidomics analysis. *Sci Total Environ*. 2017; 592:357–65. <https://doi.org/10.1016/j.scitotenv.2017.03.035> PMID: 28319722.
  46. Sapcariu SC, Kanashova T, Dilger M, Diabate S, Oeder S, Passig J, et al. Metabolic Profiling as Well as Stable Isotope Assisted Metabolic and Proteomic Analysis of RAW 264.7 Macrophages Exposed to Ship Engine Aerosol Emissions: Different Effects of Heavy Fuel Oil and Refined Diesel Fuel. *PloS one*. 2016; 11(6):e0157964. <https://doi.org/10.1371/journal.pone.0157964> PMID: 27348622; PubMed Central PMCID: PMC4922672.
  47. Wu X, Cao H, Zhao L, Song J, She Y, Feng Y. Metabolomic analysis of glycerophospholipid signatures of inflammation treated with non-steroidal anti-inflammatory drugs-induced-RAW264.7 cells using (1)H NMR and U-HPLC/Q-TOF-MS. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2016; 1028:199–215. <https://doi.org/10.1016/j.jchromb.2016.06.032> PMID: 27371817.
  48. Rattigan KM, Pountain AW, Regnault C, Achcar F, Vincent IM, Goodyear CS, et al. Metabolomic profiling of macrophages determines the discrete metabolomic signature and metabolomic interactome triggered by polarising immune stimuli. *PloS one*. 2018; 13(3):e0194126. <https://doi.org/10.1371/journal.pone.0194126> PMID: 29538444; PubMed Central PMCID: PMC5851634.
  49. Hollenbaugh JA, Montero C, Schinazi RF, Munger J, Kim B. Metabolic profiling during HIV-1 and HIV-2 infection of primary human monocyte-derived macrophages. *Virology*. 2016; 491:106–14. <https://doi.org/10.1016/j.virol.2016.01.023> PMID: 26895248; PubMed Central PMCID: PMC4834987.
  50. Groot-Kormelink PJ, Fawcett L, Wright PD, Gosling M, Kent TC. Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogates. *BMC Immunol*. 2012; 13:57. <https://doi.org/10.1186/1471-2172-13-57> PMID: 23102269; PubMed Central PMCID: PMC3542584.
  51. Victoni T, Salvator H, Abrial C, Brollo M, Porto LCS, Lagente V, et al. Human lung and monocyte-derived macrophages differ with regard to the effects of beta2-adrenoceptor agonists on cytokine release. *Respiratory research*. 2017; 18(1):126. <https://doi.org/10.1186/s12931-017-0613-y> PMID: 28637505; PubMed Central PMCID: PMC5480184.
  52. Buenestado A, Grassin-Delyle S, Guitard F, Naline E, Faisy C, Israel-Biet D, et al. Roflumilast inhibits the release of chemokines and TNF-alpha from human lung macrophages stimulated with lipopolysaccharide. *British journal of pharmacology*. 2012; 165(6):1877–90. <https://doi.org/10.1111/j.1476-5381.2011.01667.x> PMID: 21913898; PubMed Central PMCID: PMC3372837.
  53. Gill SK, Yao Y, Kay LJ, Bewley MA, Marriott HM, Peachell PT. The anti-inflammatory effects of PGE2 on human lung macrophages are mediated by the EP4 receptor. *Br J Pharmacol*. 2016; 173(21):3099–109. <https://doi.org/10.1111/bph.13565> PMID: 27460634; PubMed Central PMCID: PMC5056231.
  54. Birrell MA, Maher SA, Dekkak B, Jones V, Wong S, Brook P, et al. Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype. *Thorax*. 2015; 70(8):740–7. <https://doi.org/10.1136/thoraxjnl-2014-206592> PMID: 25939749; PubMed Central PMCID: PMC4516010.
  55. Ratcliffe MJ, Walding A, Shelton PA, Flaherty A, Dougall IG. Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages. *Eur Respir J*. 2007; 29(5):986–94. <https://doi.org/10.1183/09031936.00131606> PMID: 17331962.
  56. Briand G, Devillier P. Implication de la voie des kynurénines dans la polarisation des macrophages pulmonaires humains. *Rev Mal Respir*. 2014; 31(9):879. <https://doi.org/10.1016/j.rmr.2014.06.007>



57. Alberati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. *J Neurochem*. 1996; 66(3):996–1004. <https://doi.org/10.1046/j.1471-4159.1996.66030996.x> PMID: 8769859.
58. Lee SM, Park HY, Suh YS, Yoon EH, Kim J, Jang WH, et al. Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway. *Proc Natl Acad Sci U S A*. 2017; 114(29):E5881–E90. <https://doi.org/10.1073/pnas.1615280114> PMID: 28673995; PubMed Central PMCID: PMC5530642.
59. Maneglier B, Malleret B, Guillemin GJ, Spreux-Varoquaux O, Devillier P, Rogez-Kreuz C, et al. Modulation of indoleamine-2,3-dioxygenase expression and activity by HIV-1 in human macrophages. *Fundam Clin Pharmacol*. 2009; 23(5):573–81. <https://doi.org/10.1111/j.1472-8206.2009.00703.x> PMID: 19656212.
60. Ajamian F, Wu Y, Ebeling C, Ilarrazza R, Odemuyiwa SO, Moqbel R, et al. Respiratory syncytial virus induces indoleamine 2,3-dioxygenase activity: a potential novel role in the development of allergic disease. *Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology*. 2015; 45(3):644–59. <https://doi.org/10.1111/cea.12498> PMID: 25627660.
61. Meier MA, Ottiger M, Vogeli A, Steuer C, Bernasconi L, Thomann R, et al. Activation of the Serotonin Pathway is Associated with Poor Outcome in COPD Exacerbation: Results of a Long-Term Cohort Study. *Lung*. 2017; 195(3):303–11. <https://doi.org/10.1007/s00408-017-0004-7> PMID: 28434116.
62. Suzuki Y, Suda T, Yokomura K, Suzuki M, Fujie M, Furuhashi K, et al. Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia. *J Infect*. 2011; 63(3):215–22. <https://doi.org/10.1016/j.jinf.2011.07.003> PMID: 21784100.
63. Rogers AJ, McGeachie M, Baron RM, Gazourian L, Haspel JA, Nakahira K, et al. Metabolomic derangements are associated with mortality in critically ill adult patients. *PloS one*. 2014; 9(1):e87538. <https://doi.org/10.1371/journal.pone.0087538> PMID: 24498130; PubMed Central PMCID: PMC3907548.
64. Marshall B, Keskin DB, Mellor AL. Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. *BMC Biochem*. 2001; 2:5. <https://doi.org/10.1186/1471-2091-2-5> PMID: 11375052; PubMed Central PMCID: PMC31925.
65. Poormasjedi-Meibod MS, Jalili RB, Hosseini-Tabatabaei A, Hartwell R, Ghahary A. Immuno-regulatory function of indoleamine 2,3 dioxygenase through modulation of innate immune responses. *PloS one*. 2013; 8(8):e71044. <https://doi.org/10.1371/journal.pone.0071044> PMID: 23940687; PubMed Central PMCID: PMC3733714.
66. Blohmke CJ, Darton TC, Jones C, Suarez NM, Waddington CS, Angus B, et al. Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever. *The Journal of experimental medicine*. 2016; 213(6):1061–77. <https://doi.org/10.1084/jem.20151025> PMID: 27217537; PubMed Central PMCID: PMC4886356.
67. Fox JM, Sage LK, Poore S, Johnson S, Tompkins SM, Tripp RA. Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection. *J Leukoc Biol*. 2014; 96(3):447–52. <https://doi.org/10.1189/jlb.3AB0114-046RR> PMID: 24799604; PubMed Central PMCID: PMC4138204.
68. Yamamoto Y, Yamasuge W, Imai S, Kunisawa K, Hoshi M, Fujigaki H, et al. Lipopolysaccharide shock reveals the immune function of indoleamine 2,3-dioxygenase 2 through the regulation of IL-6/stat3 signalling. *Sci Rep*. 2018; 8(1):15917. <https://doi.org/10.1038/s41598-018-34166-4> PMID: 30374077; PubMed Central PMCID: PMC6206095.
69. Krishnan S, Ding Y, Saedi N, Choi M, Sridharan GV, Sherr DH, et al. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. *Cell reports*. 2018; 23(4):1099–111. <https://doi.org/10.1016/j.celrep.2018.03.109> PMID: 29694888; PubMed Central PMCID: PMC6392449.
70. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. *J Exp Med*. 2004; 200(5):689–95. <https://doi.org/10.1084/jem.20040416> PMID: 15337792; PubMed Central PMCID: PMC2212744.
71. Hodge S, Matthews G, Mukaro V, Ahern J, Shivam A, Hodge G, et al. Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. *American journal of respiratory cell and molecular biology*. 2011; 44(5):673–81. <https://doi.org/10.1165/rcmb.2009-0459OC> PMID: 20595463.
72. Chen H, Cowan MJ, Hasday JD, Vogel SN, Medvedev AE. Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. *J Immunol*. 2007; 179(9):6097–106. <https://doi.org/10.4049/jimmunol.179.9.6097> PMID: 17947684.

73. Armstrong J, Sargent C, Singh D. Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. *Clin Exp Immunol*. 2009; 158(1):74–83. <https://doi.org/10.1111/j.1365-2249.2009.03986.x> PMID: 19737233; PubMed Central PMCID: PMC2759061.
74. Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, et al. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. *J Pharmacol Exp Ther*. 2011; 338(3):732–40. <https://doi.org/10.1124/jpet.111.180737> PMID: 21610141.
75. Higham A, Booth G, Lea S, Southworth T, Plumb J, Singh D. The effects of corticosteroids on COPD lung macrophages: a pooled analysis. *Respiratory research*. 2015; 16:98. <https://doi.org/10.1186/s12931-015-0260-0> PMID: 26289362; PubMed Central PMCID: PMC4545868.